211100-24-2 Usage
Uses
Used in Pharmaceutical Industry:
17-trans Prostaglandin F3α is used as a research compound for investigating its potential biological activity and therapeutic applications. Due to its structural similarity to PGF3α, it may have potential uses in the development of drugs targeting prostaglandin pathways, which are involved in various physiological processes such as inflammation, blood flow regulation, and reproductive functions.
Used in Nutritional Research:
17-trans Prostaglandin F3α is used as a subject of study in nutritional research to understand the effects of trans fatty acids on human health. As a potential metabolite of trans dietary fatty acids, it may provide insights into the metabolic pathways and health implications associated with the consumption of trans fats.
Used in Biochemistry and Molecular Biology:
17-trans Prostaglandin F3α is used as a tool in biochemical and molecular biology research to explore the mechanisms of fatty acid metabolism and the role of isomers in biological systems. Its unique structure may help researchers understand the differences in biological activity between isomers and their potential impact on cellular processes.
Check Digit Verification of cas no
The CAS Registry Mumber 211100-24-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,1,1,0 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 211100-24:
(8*2)+(7*1)+(6*1)+(5*1)+(4*0)+(3*0)+(2*2)+(1*4)=42
42 % 10 = 2
So 211100-24-2 is a valid CAS Registry Number.
211100-24-2Relevant articles and documents
Regioselective allylation and propargylation using acylsilanes: Facile synthesis of PGE3 and F(3α) methyl ester
Yanagisawa,Habaue,Yamamoto
, p. 1969 - 1980 (2007/10/02)
Regioselective allylation and propargylation were achieved using acylsilanes as electrophiles and this methodology was applied to the synthesis of PGE3 and F(3α) methyl ester.
PGB3 analogs
-
, (2008/06/13)
This disclosure relates to prostaglandins of the PG3 series including PGE3, PGF3α, PGF3β, PGA3, and PGB3, to various analogs of those in racemic form, and to novel processes for making those. This disclosure also relates to certain fluorine and alkyl substituted analogs and certain acetylenic analogs of PGE3, PGF3α, PGF3β, PGA3, and PGB3 in both racemic and optically active form, and to processes for making those. These various analogs are useful for the same pharmacological purposes as the known optically active forms of PGE3, PGF3α, PGF3β, PGA3, and PGB3, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement, fertility control, and wound healing.
